STEM: Building a 21st Century Workforce to Develop Tomorrow's

  • View
    213

  • Download
    1

Embed Size (px)

Text of STEM: Building a 21st Century Workforce to Develop Tomorrow's

  • BattelleanditslogosareregisteredtrademarksofBattelleMemorialInstitute.BattelleMemorialInstitute2014.AllRightsReserved.

    Battelledoesnotengageinresearchforadvertising,salespromotion,orendorsementofourclientsinterestsincludingraisinginvestmentcapitalorrecommendinginvestmentsdecisions,orotherpublicitypurposes,orforanyuseinlitigation.

    Battelleendeavorsatalltimestoproduceworkofthehighestquality,consistentwithourcontractcommitments.However,becauseoftheresearchand/orexperimentalnatureofthisworktheclientundertakesthesoleresponsibilityfortheconsequenceofanyuseormisuseof,orinabilitytouse,anyinformation,apparatus,processorresultobtainedfromBattelle,andBattelle,itsemployees,officers,orTrusteeshavenolegalliabilityfortheaccuracy,adequacy,orefficacythereof.

  • ReportpreparedforthePharmaceuticalResearchandManufacturersofAmericaprovidedbyBattelleTechnologyPartnershipPracticeJanuary2014

  • CONTENTS:

    ExecutiveSummary.............................................................................................................i

    BiopharmaceuticalIndustryTargetsU.S.STEMEducationtoFuelInnovation,MaintainCompetitiveness..................................................................1

    U.S.Competitiveness,GlobalLeadershipatRiskDuetoSTEMShortfalls.........................3

    BiopharmaceuticalIndustry,PoweredbyaHighlySkilledSTEMWorkforce...................11

    BiopharmaceuticalCompaniesNurturingNextGenerationofSkilledWorkers..............14

    Conclusion:ArrestingSTEMDeclinetoEnsureTomorrowsNewMedicines,EconomicVitalityRequiresaLongTermCommitment....................................................................33

    Appendix...........................................................................................................................35

  • i

    ExecutiveSummary

    Continuedscientificandtechnologicalinnovationsarecriticaltofosteringsustainedeconomicgrowth,globalcompetitiveness,andmostimportantly,helpingpatientslivelonger,healthier,andmoreproductivelives.TheU.S.innovativebiopharmaceuticalindustryiscommittedtobuildingonnewscientificdiscoveriesandtechnologicaladvances,relyingonaworkforcewitheducationandskillsinscience,technology,engineering,andmath(STEM).Aroundtheworld,anincreasingnumberofcountrieshaverecognizedthatarobustSTEMskilledworkforceisneededtofuelcontinuedeconomicgrowth.STEMworkershavebeenshowntobekeydriversofinnovationand,thus,contributesignificantlytoeconomicproductivity.

    CountrieslikeChinaandSingaporehavedevelopedandimplementedstrategiesspecificallyaimedatgainingacompetitiveedgeinSTEMfields,makingmajorinvestmentsinimprovingthestateofSTEMeducationtoincreasethenumberofscientists,engineers,andotherSTEMgraduatesoverall.Asaresultoftheirinvestments,theyhavethehighestratesofscienceandmathliteracyamongOrganizationforEconomicCooperationandDevelopment(OECD)countrieswhiletheU.S.nowranksamongthebottomhalf.ThereisincreasingconcernthattheU.S.willloseitscompetitiveedgeinSTEMtalentwhichwillresultinalossofinnovativecapacityandrelatedeconomiccontributionsandeventuallyleadU.S.businessestolooktoothercountriesforneededSTEMtalent.

    TherelativedeclineinthelevelofachievementandinterestinSTEMfieldsintheU.S.hasresultedinaninadequatesupplyofworkerswithSTEMskillsandeducation,whilethedemandforSTEMtalenthascontinuedtoincrease.Tofulfillthenationslongtermpotentialforeconomicgrowth,itiscriticalthatweadvanceandimproveknowledgeinSTEMfieldsandgrowthe21stcenturyworkforceneededbytheincreasinglyknowledgebasedeconomy.STEMjobsfueleconomicgrowthinmanywaysincludingviahigherwagesandahigheremploymentmultipliermeaningSTEMbasedindustriesgenerallysupportagreaternumberofadditionaljobsacrosstheeconomycomparedwithotherindustries.

    Toharnessthenationsgreatscientificandtechnologicalpotential,government,commercial,educational,andresearchorganizationsneedtoworktogethertoimprovethestateofSTEMeducationintheU.S.andtobuildarobustSTEMworkforce.AmericasinnovativebiopharmaceuticalcompaniesareamongthoserecognizingtheneedtofindnewwaystoimprovethequalityofSTEMeducationstartingatK12andcontinuingbeyondcollegetheyrecognizethataSTEMworkforceiscriticalinanincreasinglycompetitiveglobaleconomy.Thisreportcataloguesforthefirsttimethemanywaysinwhichthenationsbiopharmaceuticalcompaniesarepartneringwithschools,investinginSTEMeducation,andbringingtheirexpertiseandresourcestobeartoimproveSTEMeducationintheU.S.

    ournationssuccessdependsonstrengtheningAmericasroleastheworldsengineofdiscoveryandinnovationleadershiptomorrowdependsonhowweeducateourstudentstodayespeciallyinscience,technology,engineeringandmath.Weknowhowimportantthisisforourhealth.Itsimportantforoursecurity.Itsimportantforourenvironment.Andweknowhowimportantitisforoureconomy.

    PresidentBarackObama

  • ii

    Keyfindingsofthereportinclude:

    InnovativebiopharmaceuticalcompaniesandtheircorporatefoundationsaremakingsignificantcontributionstoU.S.STEMeducationthroughabroadrangeoflocal,state,andnationallevelprogramsandinitiativesaimedatelementarythroughpostsecondaryeducation.Overthepastfiveyears,the24PhRMAmembercompaniesvoluntarilyreportinginformationfundedmorethan90individualinitiativesfocusedonstudentsand/orteachersinSTEMrelatedfields,themajorityofwhichhavebeenactivewithinthelastyear.

    Overthelastfiveyears,PhRMAmembercompanySTEMprogramshaveimpactedover1.6millionstudentsand17,500teachersacrosstheU.S.Onacurrentannualbasis,about500,000studentsand8,000teachersparticipateinSTEMeducationprogramssupportedbyPhRMAmembers.

    PhRMAmembercompanyprogramsareimpactingstudentsandteachersacrossthecountry,through14nationallevelprogramsthatrangefromfundingthirdpartySTEMeducationinitiatives,tosupportingscholarshipsinSTEMrelatedfields,tosponsoringSTEMrelatedcompetitionstofosterinterestinSTEMcareers.AdditionalSTEMactivitiesarebeingsupportedin26states,WashingtonD.C.,andPuertoRico,withalargerconcentrationofactivitiesinstateswithadeeperindustrypresence.

    Intotal,the24PhRMAmembercompaniesandtheirfoundationsrespondinghaveinvestedover$100millioninSTEMeducationrelatedinitiativessince2008,includingawardingnearly600individualSTEMeducationrelatedgrants.In2012alone,thesePhRMAmembercompaniesinvestedover$10millioninsupportingSTEMeducationefforts.

    Inadditiontofinancialsupport,PhRMAmembercompaniesarealsomakingsignificantinkindcontributionsbyleveragingthetalentsofnearly4,500industryemployeevolunteers,whohavecollectivelyvolunteeredalmost27,000hoursoverthepastfiveyears.Otherinkindcontributionsincludeequipmentdonationsandtheuseofcompanylaboratoryfacilities,particularlyattheK12levels,atatimewhenpublicschoolbudgetsareshrinking.

    Alargemajority(85percent)ofindustrysupportedSTEMeducationprogramsfocusontheK12levelsandareaimedatimprovingthepreparationofbothstudentsandteachers.ThissuggeststhatPhRMAmembercompaniesarefocusedonsystemicchangesinthewaySTEMeducationistaughtintheU.S.byengagingyoungerstudentsandearlyeducationteachers.

    Over30PhRMAmemberprogramsarefocusingonincreasingdiversityinSTEMfieldsbyprovidingstudentsofallbackgrounds,particularlywomenandminorities,experiencewithhandson,inquirybasedscientificlearningopportunities.

  • 1

    BiopharmaceuticalIndustryTargetsU.S.STEMEducationtoFuelInnovation,MaintainCompetitiveness

    TheU.S.knowledgeeconomy,whichfuelsresearchanddevelopment(R&D)intensivesectorssuchastheinnovativebiopharmaceuticalindustry,isincreasinglyatriskastheU.S.fallsbehindothercountriesinscience,technology,engineering,andmath(STEM)proficiencyleadingtocurrentandprojectedshortagesinhighskilledtalent.

    Developingnovel,lifesavingtherapeuticsanddiagnosticsrequiresawelleducated,trained,experiencedSTEMworkforcefromarangeofdisciplines.ThebiopharmaceuticalindustrydrawsfromabroadrangeofSTEMdegreefieldsthatspanalllevels,fromlabtechnicianstomedicalscientistsandchemists,tomathematicians,statisticians,andindustrialengineers.

    TheSTEMtalentpoolhasbeencriticaltotheindustryssuccess,and,byextension,toU.S.globalleadership.TheU.S.haslongbeenrecognizedasthegloballeaderinbiopharmaceuticalR&D,withmorethan3,500drugsandtherapeuticsindevelopmentorunderU.S.FoodandDrugAdministration(FDA)review.Inthelasttenyears,theFDAhasapprovedmorethan300newmedicines,includingthefirstmedicinetotreattheunderlyingcauseofcysticfibrosis,thefirstvaccinetopreventcervicalcancer,andthefirsttherapeuticvaccinetotreatprostatecancer.1TheU.S.biopharmaceuticalsectorsupportsatotalofnearly3.4millionjobsacrosstheeconomy,andcontributes$789billionineconomicoutputwhendirectandindirecteffectsareconsidered.TheseeconomicimpactsarefueledbytheR&Denterprise,inwhichPhRMAmember1PharmaceuticalResearchandManufacturersofAmerica,NewDrugApprovalsreports,20032011;U.S.FoodandDrugAdministration,2011BiologicalLicenseApplicationApprovals,2March2012;U.S.FoodandDrugAdministration,NewMolecularEntityApprovalsfor2011,31January2012.

  • 2

    companiesaloneinvestedanestimated$48.5billionin2012,withmostoftheseinvestmentsmadeintheU.S.ThissectorservesasthefoundationuponwhichoneoftheU.S.mostdynamicinnovationandbusinessecosystemsisbuilt.2

    GiventheimportanceofSTEMskilledworkerstodrivingcontinuedbiopharmaceuticalinnovationandtheeconomicbenefitsthataccompanyit,theindustryisdevotingresourcestoadvancingSTEMeducationintheU.S.AsrecentlystatedbyPhilBlake,theCEOofBayerCorporation,Duetoincreasingglobalcompetition,thereisgrowingdemandforaU.S.workforcethatisflexible,scientificallyliterate,andequippedwiththecriticalthinking,problemsolvingandteamworkingskillsfosteredbyaqualityscienceeducation.Toremaingloballycompetitive,wemustcommittoimprovingU.S.STEMeducationforallstudents,particularlygirlsandunderrepresentedminoritiesincludingAfricanAmericans,HispanicsandAmericanIndians.ForBayer,thatisthereasonwecreatedtheMakingScienceMakeSenseprogramandhavebeenactiveineffortstoimproveSTEMoverthepast40years.

    Asthisreportdetails,anindustrywideeffortisunderwaytoaddressdecliningtrendsinSTEMeducationintheU.S.ThereportexaminesthegrowingSTEMskillsgapintheU.S.ec